Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as sodium hyaluronate
hyaluronate · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| sodium hyaluronate | DRUG | - |
The following information on clinical trials is provided for information purposes only to allow patients and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to po...
Hyaluronate is being studied for osteoarthritis of the shoulder. Sanofi is developing it as a Phase 3 treatment in the musculoskeletal therapeutic area. The completed Phase 3 trial HUPS evaluated hyaluronate in patients with painful shoulder osteoarthritis, enrolling 602 participants in the United States.
Hyaluronate is developed by Sanofi, which trades under the ticker SNY. Sanofi is the sponsor of the Phase 3 clinical program evaluating hyaluronate for osteoarthritis of the shoulder.
Hyaluronate is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently active. The completed study, HUPS, was a randomized, double-blind trial that enrolled 602 participants with osteoarthritis of the shoulder.
Hyaluronate has been evaluated in one Phase 3 clinical trial, NCT00377624, titled HUPS: Hyalgan Use in Painful Shoulder. The trial studied osteoarthritis of the shoulder, enrolled 602 participants, was randomized and double-blind, and has been completed. It was conducted in the United States.
Yes, hyaluronate is also known as sodium hyaluronate. Both names refer to the same Sanofi compound being developed for osteoarthritis of the shoulder.